Brett H Diamond1, Vikram Jairam2, Shaharyar Zuberi3, Jessie Y Li2, Timothy J Marquis4, Charles E Rutter3,5, Henry S Park1. 1. Tufts University School of Medicine, Department of Radiation Oncology, Boston, MA 02111, USA. 2. Yale School of Medicine, Department of Therapeutic Radiology, New Haven, CT 06511, USA. 3. University of Connecticut School of Medicine, Department of Radiation Oncology, Farmington, CT 06032, USA. 4. Yale School of Medicine, Department of Medicine, New Haven, CT 06511, USA. 5. Hartford HealthCare, Department of Radiation Oncology, Hartford, CT 06106, USA.
Abstract
INTRODUCTION: Single-fraction stereotactic radiosurgery (SF-SRS) is typically used to provide local control of brain metastases. Recently, hypofractionated stereotactic radiotherapy (HF-SRT) has been utilized for large brain metastases. Data comparing these two modalities are limited for brain metastases ≤3 cm. METHODS: Patients with brain metastases receiving linear accelerator-based SF-SRS or HF-SRT were identified at three institutions. Local progression-free survival (LPFS), intracranial progression-free survival (ICPFS), overall survival (OS), and radionecrosis-free survival (RNFS) were determined from time of treatment. RESULTS: 108 patients (76 intact, 32 resected) with 184 brain metastases (142 intact, 42 resected) were included. There were no significant differences between SF-SRS and HF-SRT for intact metastases in 1-year LPFS (62.8% vs. 58.5%, p=0.631), ICPFS (56.9% vs. 55.3%, p=0.300), and OS (71.6% vs. 70.6%, p=0.096), or for resected metastases in 1-year LPFS (67.3% vs. 57.8%, p=0.288), ICPFS (64.8% vs. 57%, p=0.291), and OS (64.8% vs. 66.1%, p=0.603). There were also no significant differences in 1-year RNFS between SF-SRS and HF-SRT (92% vs. 92%, p=0.325). CONCLUSIONS: There were no significant differences in LPFS, ICPFS, OS, and RNFS between SF-SRS and HF-SRT for brain metastases ≤3 cm suggesting SF-SRS may be preferred due to similar outcomes and reduced number of fractions.
INTRODUCTION: Single-fraction stereotactic radiosurgery (SF-SRS) is typically used to provide local control of brain metastases. Recently, hypofractionated stereotactic radiotherapy (HF-SRT) has been utilized for large brain metastases. Data comparing these two modalities are limited for brain metastases ≤3 cm. METHODS: Patients with brain metastases receiving linear accelerator-based SF-SRS or HF-SRT were identified at three institutions. Local progression-free survival (LPFS), intracranial progression-free survival (ICPFS), overall survival (OS), and radionecrosis-free survival (RNFS) were determined from time of treatment. RESULTS: 108 patients (76 intact, 32 resected) with 184 brain metastases (142 intact, 42 resected) were included. There were no significant differences between SF-SRS and HF-SRT for intact metastases in 1-year LPFS (62.8% vs. 58.5%, p=0.631), ICPFS (56.9% vs. 55.3%, p=0.300), and OS (71.6% vs. 70.6%, p=0.096), or for resected metastases in 1-year LPFS (67.3% vs. 57.8%, p=0.288), ICPFS (64.8% vs. 57%, p=0.291), and OS (64.8% vs. 66.1%, p=0.603). There were also no significant differences in 1-year RNFS between SF-SRS and HF-SRT (92% vs. 92%, p=0.325). CONCLUSIONS: There were no significant differences in LPFS, ICPFS, OS, and RNFS between SF-SRS and HF-SRT for brain metastases ≤3 cm suggesting SF-SRS may be preferred due to similar outcomes and reduced number of fractions.
Authors: Bree R Eaton; Michael J LaRiviere; Michael J La Riviere; Sungjin Kim; Roshan S Prabhu; Kirtesh Patel; Shravan Kandula; Nelson Oyesiku; Jeffrey Olson; Walter Curran; Hui-Kuo Shu; Ian Crocker Journal: J Neurooncol Date: 2015-04-11 Impact factor: 4.130
Authors: Benjamin H Kann; Henry S Park; Skyler B Johnson; Veronica L Chiang; James B Yu Journal: J Natl Compr Canc Netw Date: 2017-12 Impact factor: 11.908
Authors: Achal Singh Achrol; Robert C Rennert; Carey Anders; Riccardo Soffietti; Manmeet S Ahluwalia; Lakshmi Nayak; Solange Peters; Nils D Arvold; Griffith R Harsh; Patricia S Steeg; Steven D Chang Journal: Nat Rev Dis Primers Date: 2019-01-17 Impact factor: 52.329
Authors: Jeffrey I Traylor; Ahmed Habib; Rajan Patel; Matthew Muir; Ron Gadot; Tina Briere; Debra N Yeboa; Jing Li; Ganesh Rao Journal: J Neurooncol Date: 2019-07-16 Impact factor: 4.130
Authors: Alexander K Kwon; Steven J Dibiase; Brian Wang; Samuel L Hughes; Barry Milcarek; Yunping Zhu Journal: Cancer Date: 2009-02-15 Impact factor: 6.860
Authors: Siyu Shi; Navjot Sandhu; Michael C Jin; Elyn Wang; Joseph Abi Jaoude; Kirsten Schofield; Carrie Zhang; Elisa Liu; Iris C Gibbs; Steven L Hancock; Steven D Chang; Gordon Li; Melanie Hayden-Gephart; John R Adler; Scott G Soltys; Erqi L Pollom Journal: Int J Radiat Oncol Biol Phys Date: 2019-11-27 Impact factor: 7.038
Authors: Kerstin A Eitz; Simon S Lo; Hany Soliman; Arjun Sahgal; Aimee Theriault; Mark B Pinkham; Matthew C Foote; Andrew J Song; Wenyin Shi; Kristin J Redmond; Chenchen Gui; Aryavarta M S Kumar; Mitchell Machtay; Bernhard Meyer; Stephanie E Combs Journal: JAMA Oncol Date: 2020-12-01 Impact factor: 31.777
Authors: Jill S Remick; Emily Kowalski; Rahul Khairnar; Kai Sun; Emily Morse; Hua-Ren R Cherng; Yannick Poirier; Narottam Lamichhane; Stewart J Becker; Shifeng Chen; Akshar N Patel; Young Kwok; Elizabeth Nichols; Pranshu Mohindra; Graeme F Woodworth; William F Regine; Mark V Mishra Journal: Radiat Oncol Date: 2020-05-28 Impact factor: 3.481